HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sweden Drops Plans For Max Levels In Supplements After Commission Consultation

Executive Summary

Sweden will not introduce proposed limits for vitamin D and iodine in dietary supplements after the European Commission warned it would create a disproportionate barrier to trade with other EU member states.

You may also be interested in...



Sweden Proposes Maximum Levels For Vitamin D And Iodine In Supplements

Concerned about adverse health effects, Sweden wants to limit the amount of vitamin D and iodine in supplements from January 2024. In setting maximum levels for certain vitamins and minerals, Sweden will join a host of European countries introducing national rules in the absence of direction from the European Commission. 

Bayer Consumer Health Names New President In Surprise Move

Heiko Schipper is departing for Unilever with Bayer Consumer Health promoting Julio Triana to take over just days before a capital markets day which will set the future direction of the business.

Haleon Surprises Analysts With Stand-Out Cold & Flu Showing In Q4

In describing Haleon’s Q4 showing as a “strong finish to the year,” Bernstein’s Bruno Monteyne pointed to “remarkable strength in respiratory health,” with the category resoundingly beating analysts’ consensus estimates of a 2.5% decline.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153699

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel